Merrimack to Present Research on Multiple Programs at the 2015 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

CAMBRIDGE, Mass., Nov. 3, 2015 /PRNewswire/ -- Merrimack (Nasdaq: MACK) today announced that it will present research on several of its therapeutic candidates at the 2015 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, November 5-9, 2015 at Hynes Convention Center in Boston. Presentations include recent preclinical data from Merrimack's antibody engineering technology platforms.

Data will be presented in three poster sessions:

Poster Sessions

• Istiratumab (MM-141), a bispecific antibody co-targeting IGF-1R and ErbB3, potentiates the activity of immune checkpoint inhibitors (Abstract #A89)
  Poster Session A
  Session Title: Immune Modulators
  Friday, November 6, 2015, 12:15 PM - 3:15 PM ET
  Exhibit Hall C-D

• MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancer cells harboring EGFR extracellular domain mutations (Abstract #LB-B05)
  Poster Session B
  Session Title: EGFR/Her2
  Saturday, November 7, 2015, 12:30 PM – 3:30 PM ET
  Exhibit Hall C-D

• Inhibition of ERBB3 with MM-121, IGF1-R with MM-141 or Met with MM-131 increases the activity of EGFR inhibitor MM-151 in colorectal cancer models expressing multiple resistance ligands (Abstract #LB-C25)
  Poster Session C
  Session Title: Drug Resistance and Modifiers
  Sunday, November 8, 2015, 12:30 PM – 3:30 PM ET
  Exhibit Hall C-D

About Merrimack

Merrimack is a fully integrated biopharmaceutical company that views cancer as a complex engineering challenge. Through systems biology, which brings together the fields of biology, computing and engineering, Merrimack aims to decrease uncertainty in drug development and clinical validation, and move discovery efforts beyond trial and error. Such an approach has the potential to make individualized treatment of patients a reality. Merrimack's first commercial product, ONIVYDE™ (irinotecan liposome injection), was approved by the U.S. FDA on October 22, 2015.With four additional candidates in clinical studies, several in preclinical development and multiple biomarkers designed to support patient selection, Merrimack is building one of the most robust oncology pipelines in the industry. For more information, please visit Merrimack's website at www.merrimack.com or connect on Twitter at @MerrimackPharma.

Forward-Looking Statements

Any statements in this press release about future expectations, plans and prospects for Merrimack constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, as amended. Actual results may differ materially from those indicated by such forward-looking statements. Merrimack anticipates that subsequent events and developments will cause its views to change. However, while Merrimack may elect to update these forward-looking statements at some point in the future, Merrimack specifically disclaims any obligation to do so.

CONTACTS:
Media Contact:
Dana Robie
Merrimack
617-441-7408
[email protected]

Investor Contact:
Geoffrey M. Grande, CFA
Merrimack
617-441-7602
[email protected]

SOURCE Merrimack

Related Links

http://www.merrimack.com